<DOC>
	<DOCNO>NCT01151605</DOCNO>
	<brief_summary>This study help u understand possible beneficial effect insulin inflammation . Inflamamtion consider cause atherosclerosis heart disease .</brief_summary>
	<brief_title>The Suppression Toll Like Receptors Insulin</brief_title>
	<detailed_description>Obesity type 2 diabetes major health problem United States world . Both condition characterize increase inflammation oxidative stress associate increase risk cardiovascular disease . Our previous work show insulin exerts prompt powerful anti-inflammatory effect , circulate blood cell plasma healthy subject critically ill patient . Toll like receptor ( TLRs ) recognize bacterial viral product like endotoxin virus major determinant inflammatory response foreign pathogen . In view recent data show TLRs recognize range molecule proteins pathogenic source like saturated lipid TLRs involve pathogenesis atherosclerosis lead cardiovascular disease insulin resistance lead type 2 diabetes ( DM ) hypothesize insulin infusion suppresses TLRs expression . Our preliminary data show insulin infusion 4 hour reduces level many TLRs thus might protect inflammation induced condition We therefore propose investigate , detail , effect infuse different dos insulin TLRs mRNA protein level activity obese DM subject long infusion period large number subject circulate white blood cell fat tissue . Also compare baseline level TLRs TLRs related protein well modulation insulin normal , obese DM subject .</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>INCLUSION CRITERIA Lean Group : 1 . Age : 20 65 year age inclusive 2 . Sex : male female 3 . Normal fast plasma glucose ( 65100 mg/dl ) 4 . Normal BMI ( 2025 ) Obese Group : 1 . Age : 20 65 year age inclusive 2 . Sex : male female 3 . Normal fast plasma glucose ( 65100 mg/dl ) 4 . BMI &gt; 30 DM Group : 1 . Type 2 Diabetes Mellitus 2 . Age : 20 65 year age inclusive 3 . Sex : male female 4 . BMI &gt; 30 5 . Hba1c &lt; 8 % 6 . If statin , angiotensin convert enzyme inhibitor , angiotensin receptor blocker low dose aspirin , stable dose one month . EXCLUSION CRITERIA 1 . Pregnancy 2 . Congestive heart failure 3 . Heart Rate &lt; 50 beat /minute 4 . Sick Sinus Syndrome 5 . Second third degree heart block 6 . Blood pressure &lt; 80 mm systolic &gt; 160/100 mmHg 7 . Coronary event procedure ( myocardial infarction , unstable angina , coronary artery bypass surgery coronary angioplasty ) previous three month 8 . Hepatic disease ( transaminase &gt; 3 time normal ) 9 . Renal impairment ( serum creatinine &gt; 1.5 ) 10 . History drug alcohol abuse within past one year 11 . Participation concurrent clinical trial 12 . Potassium ( K+ ) value &lt; 3.5 meq/l &gt; 5.5 meq/l ) 13 . Any lifethreatening , noncardiac disease 14 . Use investigational agent therapeutic regimen within 30 day study 15 . Type 2 diabetic thiazolidinediones and/ insulin 16 . Subjects steroid , NSAIDS antioxidants 17 . Patients take exenatide sitaglipin loop diuretic 18 . Anemia ( Hemoglobin level le 12gm/dl female 13gm/dl male ) 19 ) Allergy lidocaine</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>